Experts say that Canadian parents use unregulated cannabinoids for seizure control in children with neurologic conditions like epilepsy, and clinical trials are needed to inform doctors and parents on prescribing.
New study finds that a single dose of cannabidiol in rats with symptoms of depression is highly effective, eliminating the symptoms on the same day and maintaining the beneficial effects for a week.
Research from King’s College London has found that a single dose of the cannabis extract cannabidiol can help reduce brain function abnormalities seen in people with psychosis.
Researchers at the Center for BrainHealth® at the University of Texas at Dallas investigated the effects on the brain of concurrent cannabis and nicotine use, versus the use of solely cannabis and solely nicotine.
A large-scale genetic study found that some of the same genes associated with the use of cannabis are also associated with certain personality types and psychiatric conditions.
Scientists have found the primary psychoactive component of marijuana in 63% of breast milk samples for up to six days after the mother’s last reported use.
EHP-101 has shown promise for the modulation of relevant multiple sclerosis targets, having PPARγ and CB2-mediated anti-inflammatory activity, and the potential to enhance remyelination.
The project will investigate the pain relief properties of CBD oil by exploring its mechanism of action in pain and associated depression and anxiety.
A drug policy researcher is proposing a suite of changes to overhaul the Multi-Criteria Drug Harm Scale, which informs drug policies across Europe.